Table 1 Characteristics of advanced pancreatic cancer patients with baseline and week-6 measurements
From: CA19–9 decrease and survival according to platelet level in patients with advanced pancreatic cancer
Characteristic* | N = 200 |
|---|---|
Age | |
Median, IQR | 55 (50–62) |
Sex (Male/Female) | |
Male | 127 (63.5%) |
Female | 73 (36.5%) |
KPS | |
90–100 | 169 (84.5%) |
70–80 | 31 (15.5%) |
Prediagnosis body mass index | |
Median, IQR | 22.8 (21.0–25.0) |
Diabetes Mellitus | |
Absent | 152 (76.0%) |
Present | 48 (24.0%) |
Location | |
Head/Uncinate | 73 (36.5%) |
Body/tail | 124 (62.0%) |
Overlapping sites | 3 (1.5%) |
Stage | |
III | 22 (11.0%) |
IV | 178 (89.0%) |
Liver metastasis | |
Absent | 53 (26.5%) |
Present | 147 (73.5%) |
Baseline CA19–9, U/ml | |
Median, IQR | 1364.5 (203.6–9094.3) |
CA19–9 change† | |
Median, IQR | −0.22 ([− 0.60]-0.088) |
Baseline Platelet (×109/L) | |
Median, IQR | 195 (153.0–235.3) |
Chemotherapy regimen | |
Gemcitabine monotherapy | 34 (17.0%) |
Gemcitabine plus 5-Fu | 18 (9.0%) |
Gemcitabine plus nab-PTX | 16 (8.0%) |
Gemcitabine plus DDP | 9 (4.5%) |
Nab-PTX plus S-1‡ | 123 (61.5%) |
Radiotherapy | |
Yes | 16 (8.0%) |
No | 184 (92.0%) |